Hangzhou Lingye Pharmaceutical Technology

Hangzhou Lingye Pharmaceutical Technology is a specialized pharmaceutical company headquartered in Hangzhou, China, focusing on drug crystal form research and high-end formulation development. The company leverages its proprietary crystal engineering and drug delivery platforms to develop improved versions of existing therapeutics, primarily through the 505(b)(2) regulatory pathway. Lingye's internal pipeline includes candidates for central nervous system disorders and oncology, with its lead program, LY-001, in clinical development for epilepsy. Beyond its own R&D, the company provides comprehensive CRO and CDMO services, assisting global partners with solid-state chemistry and complex formulation challenges. Founded in 2010 by Dr. Sheng Luan, Lingye has established itself as a leader in the Chinese pharmaceutical technology sector.